Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1/2 trial. Grimley M, Davies SM, Shrestha A, Shova A, et al. Nat Med 2025;31:2204-2212.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Grimley M, Davies SM, Shrestha A, Shova A, et al. Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1/2 trial. Nat Med 2025;31:2204-2212.
PMID: 40419809